Physician profile
Mohamed Atta
NPI 1417912262
$65,189.85
in general payments reported to CMS, 2019-2025
15 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,163 · 2021: $3,820 · 2022: $15K · 2023: $7,834 · 2024: $9,648 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Honoraria: $4,865 · Travel and Lodging: $4,494 · Food and Beverage: $1,380 · Education: $17.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,025.00 |
| Honoraria | $4,865.00 |
| Travel and Lodging | $4,494.38 |
| Food and Beverage | $1,380.34 |
| Education | $17.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $21,713.07 | 2019-2025 | |
| Horizon Therapeutics Plc | $16,224.21 | 2021-2023 | Procysbi |
| Chiesi USA, INC. | $9,073.43 | 2022-2025 | Elfabrio |
| Glaxosmithkline, LLC. | $6,601.43 | 2024-2025 | Benlysta |
| Amgen INC. | $6,282.34 | 2019-2024 | Procysbi |
| Calliditas Therapeutics US INC. | $3,000.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $1,652.41 | 2023-2024 | |
| Eli Lilly and Company | $500.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2025 | |
| Travere Therapeutics, INC. | $17.97 | 2023-2025 | Filspari |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Atta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.